Market closedNon-fractional

Actinium Pharmaceuticals/ATNM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Ticker

ATNM

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology

Headquarters

New York, United States

Employees

49

ATNM Metrics

BasicAdvanced
$208M
Market cap
-
P/E ratio
-$1.71
EPS
0.08
Beta
-
Dividend rate
$208M
0.08
10.587
10.424
3.263
4.519
-32.79%
-91.92%
2,336.574
4.64
4.64
-4.765
-10.00%
10.01%
-49.31%
6.13%

What the Analysts think about ATNM

Analyst Ratings

Majority rating from 7 analysts.
Buy

ATNM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.6M
-7.53%
Profit margin
0.00%
NaN%

ATNM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 40.38%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.58
-$0.49
-$0.34
-$0.31
-
Expected
-$0.48
-$0.53
-$0.54
-$0.52
-$0.41
Surprise
20.83%
-7.84%
-37.04%
-40.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Actinium Pharmaceuticals stock?

Actinium Pharmaceuticals (ATNM) has a market cap of $208M as of July 06, 2024.

What is the P/E ratio for Actinium Pharmaceuticals stock?

The price to earnings (P/E) ratio for Actinium Pharmaceuticals (ATNM) stock is 0 as of July 06, 2024.

Does Actinium Pharmaceuticals stock pay dividends?

No, Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Actinium Pharmaceuticals dividend payment date?

Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders.

What is the beta indicator for Actinium Pharmaceuticals?

Actinium Pharmaceuticals (ATNM) has a beta rating of 0.08. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Actinium Pharmaceuticals stock

Buy or sell Actinium Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing